Skip to main content

Advertisement

Fig. 2 | Journal of Biomedical Science

Fig. 2

From: Cancer immunotherapies targeting the PD-1 signaling pathway

Fig. 2

History of PD-1 research. Abbreviations: FIM, first in man; approved, FDA-approved; NCT, “National Clinical Trial” registry number in ClinicalTrials.gov in the United States; FIM Pembrolizumab (P07990/MK-3475-001/KEYNOTE-001), NCT01295827; FIM Pidilizumab (CT-011), NCT00532259; FIM BMS-936559 (MDX-1105), NCT00729664; FIM Atezolizumab, NCT01693562; FIM Durvalumab (MEDI4736), NCT01693562; FIM Avelumab, NCT01772004

Back to article page